• January 5, 2016Chairman’s Annual Update
Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 22 Jun 2016

    Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
    Read More


  • 15 Jun 2016

    Agenus to Present at the 2016 JMP Securities Life Sciences Conference
    Read More


  • 09 Jun 2016

    Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
    Read More


  • 08 Jun 2016

    Agenus to Webcast Annual Meeting of Stockholders
    Read More


  • 02 Jun 2016

    Agenus to Present at the Jefferies 2016 Healthcare Conference
    Read More


  • 19 May 2016

    Agenus Appoints Ulf Wiinberg to Board of Directors
    Read More